Gut Microbiota and Inflammatory Bowel Disease: The Role of Antibiotics in Disease Management

References

• Dominguez-Bello MG, Costello EK, Contreras M, . Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci U S A. 2010;107(26):11971–11975
   PubMed Web of Science ®Google Scholar
• Eggesbo M, Moen B, Peddada S, . Development of gut microbiota in infants not exposed to medical interventions. APMIS. 2011;119(1):17–35
   PubMed Web of Science ®Google Scholar
• Johansson MA, Saghafian-Hedengren S, Haileselassie Y, . Early-life gut bacteria associate with IL-4-, IL-10- and IFN-g production at two years of age. PLoS One. 2012;7(11):e49315
   PubMedGoogle Scholar
• Penders J, Thijs C, Vink C, . Factors influencing the composition of the intestinal microbiota in early infancy. Pediatrics. 2006;118(2):511–521
   PubMed Web of Science ®Google Scholar
• Azcárate-Peril MA, Sikes M, Bruno-Bárcena JM. The intestinal microbiota, gastrointestinal environment and colorectal cancer: a putative role for probiotics in prevention of colorectal cancer? Am J Physiol Gastrointest Liver Physiol. 2011;301(3):G401–G424
   PubMedGoogle Scholar
• Yatsunenko T, Rey FE, Manary MJ, . Human gut microbiome viewed across age and geography. Nature. 2012;486(7402):222–227
   PubMed Web of Science ®Google Scholar
• Lee S, Sung J, Lee J, Ko G. Comparison of the gut microbiotas of healthy adult twins living in South Korea and the United States. Appl Environ Microbiol. 2011;77(20):7433–7437
   PubMed Web of Science ®Google Scholar
• Lin A, Bik EM, Costello EK, . Distinct distal gut microbiome diversity and composition in healthy children from Bangladesh and the United States. PLoS One. 2013;8(1):e53838
   PubMed Web of Science ®Google Scholar
• Martínez I, Muller CE, Walter J. Long-term temporal analysis of the human fecal microbiota revealed a stable core of dominant bacterial species. PLoS One. 2013;8(7):e69621
   PubMedGoogle Scholar
• Biedermann L, Zeitz J, Mwinyi J, . Smoking cessation induces profound changes in the composition of the intestinal microbiota in humans. PLoS One. 2013;8(3):e59260
   PubMed Web of Science ®Google Scholar
• Leone V, Chang EB, Devkota S. Diet, microbes, and host genetics: the perfect storm in inflammatory bowel diseases. J Gastroenterol. 2013;48(3):315–321
   PubMed Web of Science ®Google Scholar
• . Structure, function and diversity of the healthy human microbiome. Nature. 2012;486(7402):207–214
   PubMed Web of Science ®Google Scholar
• David LA, Maurice CF, Carmody RN, . Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505(7484):559–563
   PubMed Web of Science ®Google Scholar
• Fang S, Evans RM. Microbiology: Wealth management in the gut. Nature. 2013;500(7464):538–539
   PubMedGoogle Scholar
• Thompson-Chagoyan OC, Fallani M, Maldonado J, . Faecal microbiota and short-chain fatty acid levels in faeces from infants with cow's milk protein allergy. Int Arch Allergy Immunol. 2011;156(3):325–332
   PubMed Web of Science ®Google Scholar
• Tjellström B, Stenhammar L, Högberg L, . Gut microflora associated characteristics in first-degree relatives of children with celiac disease. Scand J Gastroenterol. 2007;42(10):1204–1208
   PubMed Web of Science ®Google Scholar
• Collado MC, Cernada M, Baüerl C, Vento M, Pérez-Martinez G. Microbial ecology and host-microbiota interactions during early life stages. Gut Microbes. 2012;3(4):352–365
   PubMed Web of Science ®Google Scholar
• Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140(6):1785–1794
   PubMed Web of Science ®Google Scholar
• Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis. 2006;12( Suppl 1):S3–S9
   PubMed Web of Science ®Google Scholar
• Devkota S, Wang Y, Musch MW, . Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/- mice. Nature. 2012;487(7405):104–108
   PubMed Web of Science ®Google Scholar
• Sellon RK, Tonkonogy S, Schultz M, . Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun. 1998;66(11):5224–5231
   PubMed Web of Science ®Google Scholar
• Kim SC, Tonkonogy SL, Albright CA, . Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria. Gastroenterology. 2005;128(4):891–906
   PubMed Web of Science ®Google Scholar
• Gillevet P, Sikaroodi M, Keshavarzian A, Mutlu EA. Quantitative assessment of the human gut microbiome using multitag pyrosequencing. Chem Biodivers. 2010;7(5):1065–1075
   PubMedGoogle Scholar
• Fite A, Macfarlane S, Furrie E, . Longitudinal analyses of gut mucosal microbiotas in ulcerative colitis in relation to patient age and disease severity and duration. J Clin Microbiol. 2013;51(3):849–856
   PubMedGoogle Scholar
• Walker AW, Sanderson JD, Churcher C, . High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol. 2011;11:7
   PubMed Web of Science ®Google Scholar
• Sokol H, Seksik P, Furet JP, . Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis. 2009;15(8):1183–1189
   PubMed Web of Science ®Google Scholar
• Virta L, Auvinen A, Helenius H, Huovinen P, Kolho KL. Association of repeated exposure to antibiotics with the development of pediatric Crohn's disease—a nationwide, register-based Finnish case-control study. Am J Epidemiol. 2012;175(8):775–784
   PubMedGoogle Scholar
• Shaw SY, Blanchard JF, Bernstein CN. Association between early childhood otitis media and pediatric inflammatory bowel disease: an exploratory population-based analysis. J Pediatr. 2013;162(3):510–514
   PubMedGoogle Scholar
• Kronman MP, Zaoutis TE, Haynes K, Feng R, Coffin SE. Antibiotic exposure and IBD development among children: a population-based cohort study. Pediatrics. 2012;130(4):e794–e803
   PubMed Web of Science ®Google Scholar
• Shaw SY, Blanchard JF, Bernstein CN. Association between the use of antibiotics and new diagnoses of Crohn's disease and ulcerative colitis. Am J Gastroenterol. 2011;106(12):2133–2142
   PubMed Web of Science ®Google Scholar
• Ananthakrishnan AN. Environmental risk factors for inflammatory bowel disease. Gastroenterol Hepatol (NY). 2013;9(6):367–374
   PubMedGoogle Scholar
• Morgan XC, Tickle TL, Sokol H, . Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 2012;13(9):R79
   PubMed Web of Science ®Google Scholar
• Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol. 2009;104(2):437–443
   PubMed Web of Science ®Google Scholar
• Bibiloni R, Fedorak RN, Tannock GW, . VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol. 2005;100(7):1539–1546
   PubMed Web of Science ®Google Scholar
• Tursi A, Brandimarte G, Papa A, . Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol. 2010;105(10):2218–2227
   PubMed Web of Science ®Google Scholar
• Sood A, Midha V, Makharia GK, . The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7(11):1202–1209
   PubMed Web of Science ®Google Scholar
• Tursi A, Brandimarte G, Giorgetti GM, Forti G, Modeo ME, Gigliobianco A. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit. 2004;10(11):PI126–PI131
   PubMed Web of Science ®Google Scholar
• Venturi A, Gionchetti P, Rizzello F, . Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther. 1999;13(8):1103–1108
   PubMed Web of Science ®Google Scholar
• Mimura T, Rizzello F, Helwig U, . Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut. 2004;53(1):108–114
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Venturi A, . Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119(2):305–309
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Helwig U, . Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology. 2003;124(5):1202–1209
   PubMed Web of Science ®Google Scholar
• Oliva S, Di Nardo G, Ferrari F, . Randomised clinical trial: the effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis. Aliment Pharmacol Ther. 2012;35(3):327–334
   PubMedGoogle Scholar
• Bousvaros A, Guandalini S, Baldassano RN, . A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis. 2005;11(9):833–839
   PubMedGoogle Scholar
• Laake KO, Bjørneklett A, Aamodt G, . Outcome of four weeks' intervention with probiotics on symptoms and endoscopic appearance after surgical reconstruction with a J-configurated ileal-pouch-anal-anastomosis in ulcerative colitis. Scand J Gastroenterol. 2005;40(1):43–51
   PubMed Web of Science ®Google Scholar
• Wildt S, Nordgaard I, Hansen U, Brockmann E, Rumessen JJ. A randomised double-blind placebo-controlled trial with Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis BB-12 for maintenance of remission in ulcerative colitis. J Crohns Colitis. 2011;5(2):115–121
   PubMed Web of Science ®Google Scholar
• Van Gossum A, Dewit O, Louis E, . Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after Ileo-caecal resection. Inflamm Bowel Dis. 2007;13(2):135–142
   PubMed Web of Science ®Google Scholar
• Marteau P, Lémann M, Seksik P, . Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial. Gut. 2006;55(6):842–847
   PubMedGoogle Scholar
• Schultz M, Timmer A, Herfarth HH, Sartor RB, Vanderhoof JA, Rath HC. Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol. 2004;4:5
   PubMed Web of Science ®Google Scholar
• Prantera C, Scribano ML, Falasco G, Andreoli A, Luzi C. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut. 2002;51(3):405–409
   PubMed Web of Science ®Google Scholar
• Guslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci. 2000;45(7):1462–1464
   PubMed Web of Science ®Google Scholar
• Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol. 2003;15(6):697–698
   PubMed Web of Science ®Google Scholar
• Fujimori S, Tatsuguchi A, Gudis K, . High dose probiotic and prebiotic cotherapy for remission induction of active Crohn's disease. J Gastroenterol Hepatol. 2007;22(8):1199–1204
   PubMedGoogle Scholar
• Tsuda Y, Yoshimatsu Y, Aoki H, . Clinical effectiveness of probiotics therapy (BIO-THREE) in patients with ulcerative colitis refractory to conventional therapy. Scand J Gastroenterol. 2007;42(11):1306–1311
   PubMed Web of Science ®Google Scholar
• Matthes H, Krummenerl T, Giensch M, Wolff C, Schulze J. Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN). BMC Complement Altern Med. 2010;10:13
   PubMed Web of Science ®Google Scholar
• Kruis W, Fric P, Pokrotnieks J, . Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004;53(11):1617–1623
   PubMed Web of Science ®Google Scholar
• Kato K, Mizuno S, Umesaki Y, . Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther. 2004;20(10):1133–1141
   PubMed Web of Science ®Google Scholar
• Ishikawa H, Akedo I, Umesaki Y, Tanaka R, Imaoka A, Otani T. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr. 2003;22(1):56–63
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. Am J Gastroenterol. 2009;104(2):465–483
   PubMed Web of Science ®Google Scholar
• Wang SL, Wang ZR, Yang CQ. Meta-analysis of broad-spectrum antibiotic therapy in patients with active inflammatory bowel disease. Exp Ther Med. 2012;4(6):1051–1056
   PubMed Web of Science ®Google Scholar
• Feller M, Huwiler K, Schoepfer A, Shang A, Furrer H, Egger M. Long-term antibiotic treatment for Crohn's disease: systematic review and meta-analysis of placebo-controlled trials. Clin Infect Dis. 2010;50(4):473–480
   PubMed Web of Science ®Google Scholar
• Hovde Ø, Moum BA. Epidemiology and clinical course of Crohn's disease: results from observational studies. World J Gastroenterol. 2012;18(15):1723–1731
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, Zinsmeister AR, Sandborn WJ, Loftus EV Jr. Surgery in a population-based cohort of Crohn's disease from Olmsted County, Minnesota (1970–2004). Am J Gastroenterol. 2012;107(11):1693–1701
   PubMed Web of Science ®Google Scholar
• Debruyn JC, Soon IS, Hubbard J, Wrobel I, Panaccione R, Kaplan GG. Nationwide temporal trends in incidence of hospitalization and surgical intestinal resection in pediatric inflammatory bowel diseases in the United States from 1997 to 2009. Inflamm Bowel Dis. 2013;19(11):2423–2432
   PubMed Web of Science ®Google Scholar
• Buisson A, Chevaux JB, Allen PB, Bommelaer G, Peyrin-Biroulet L. Review article: the natural history of postoperative Crohn's disease recurrence. Aliment Pharmacol Ther. 2012;35(6):625–633
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Bamba T, Umegae S, Matsumoto K. The impact of early endoscopic lesions on the clinical course of patients following ileocolonic resection for Crohn's disease: a 5-year prospective cohort study. United European Gastro J. 2013;1(4):294–298
   PubMed Web of Science ®Google Scholar
• Dey N, Soergel DA, Repo S, Brenner SE. Association of gut microbiota with post-operative clinical course in Crohn's disease. BMC Gastroenterol. 2013;13(1):131
   PubMedGoogle Scholar
• Neut C, Bulois P, Desreumaux P, . Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease. Am J Gastroenterol. 2002;97(4):939–946
   PubMed Web of Science ®Google Scholar
• Herfarth HH, Katz JA, Hanauer SB, . Ciprofloxacin for the prevention of postoperative recurrence in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2013;19(5):1073–1079
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Hiele M, Geboes K, . Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology. 1995;108(6):1617–1621
   PubMed Web of Science ®Google Scholar
• Mañosa M, Cabré E, Bernal I, . Addition of metronidazole to azathioprine for the prevention of postoperative recurrence of Crohn's disease: a randomized, double-blind, placebo-controlled trial. Inflamm Bowel Dis. 2013;19(9):1889–1895
   PubMedGoogle Scholar
• D'Haens GR, Vermeire S, van Assche G, . Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology. 2008;135(4):1123–1129
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, van Assche G, Vermeire S, . Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2005;128(4):856–861
   PubMed Web of Science ®Google Scholar
• Bassetti M, Merelli M, Temperoni C, Astilean A. New antibiotics for bad bugs: where are we? Ann Clin Microbiol Antimicrob. 2013;12(1):22
   PubMed Web of Science ®Google Scholar
• Jakobsson HE, Jernberg C, Andersson AF, Sjolund-Karlsson M, Jansson JK, Engstrand L. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome. PLoS One. 2010;5(3):e9836
   PubMed Web of Science ®Google Scholar
• Talley NJ, Abreu MT, Achkar JP, . An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011;106( Suppl 1):S2–S25
   PubMed Web of Science ®Google Scholar
• Arnold GL, Beaves MR, Pryjdun VO, Mook WJ. Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm Bowel Dis. 2002;8(1):10–15
   PubMed Web of Science ®Google Scholar
• Leiper K, Martin K, Ellis A, Watson AJ, Morris AI, Rhodes JM. Clinical trial: randomized study of clarithromycin versus placebo in active Crohn's disease. Aliment Pharmacol Ther. 2008;27(12):1233–1239
   PubMedGoogle Scholar
• Selby W, Pavli P, Crotty B, . Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology. 2007;132(7):2313–2319
   PubMed Web of Science ®Google Scholar
• Sutherland L, Singleton J, Sessions J, . Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut. 1991;32(9):1071–1075
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Okamura S, Oshimoto H, Kobayashi R, Mori M. Metronidazole plus ciprofloxacin therapy for active Crohn's disease. Intern Med. 2003;42(4):318–321
   PubMedGoogle Scholar
• Steinhart AH, Feagan BG, Wong CJ, . Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology. 2002;123(1):33–40
   PubMedGoogle Scholar
• Levine A, Turner D. Combined azithromycin and metronidazole therapy is effective in inducing remission in pediatric Crohn's disease. J Crohns Colitis. 2011;5(3):222–226
   PubMed Web of Science ®Google Scholar
• Prantera C, Lochs H, Grimaldi M, Danese S, Scribano ML, Gionchetti P. Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. Gastroenterology. 2012;142(3):473–481
   PubMed Web of Science ®Google Scholar
• Prantera C, Lochs H, Campieri M, . Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther. 2006;23(8):1117–1125
   PubMed Web of Science ®Google Scholar
• Prantera C, Kohn A, Mangiarotti R, Andreoli A, Luzi C. Antimycobacterial therapy in Crohn's disease: results of a controlled, double-blind trial with a multiple antibiotic regimen. Am J Gastroenterol. 1994;89(4):513–518
   PubMedGoogle Scholar
• Shafran I, Burgunder P. Adjunctive antibiotic therapy with rifaximin may help reduce Crohn's disease activity. Dig Dis Sci. 2010;55(4):1079–1084
   PubMed Web of Science ®Google Scholar
• Gevers D, Kugathasan S, Denson LA, . The treatment-naive microbiome in new-onset Crohn's disease. Cell Host Microbe. 2014;15(3):382–392
   PubMed Web of Science ®Google Scholar
• Looft T, Allen HK. Collateral effects of antibiotics on mammalian gut microbiomes. Gut Microbes. 2012;3(5):463–467
   PubMed Web of Science ®Google Scholar
• Schwartz DA, Loftus EV Jr, Tremaine WJ, . The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology. 2002;122(4):875–880
   PubMed Web of Science ®Google Scholar
• Pittet V, Juillerat P, Michetti P, . Appropriateness of therapy for fistulizing Crohn's disease: findings from a national inflammatory bowel disease cohort. Aliment Pharmacol Ther. 2010;32(8):1007–1016
   PubMed Web of Science ®Google Scholar
• Thia KT, Mahadevan U, Feagan BG, . Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2009;15(1):17–24
   PubMed Web of Science ®Google Scholar
• West RL, Van Der Woude CJ, Hansen BE, . Clinical and endosonographic effect of ciprofloxacin on the treatment of perianal fistulae in Crohn's disease with infliximab: a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2004;20(11–12):1329–1336
   PubMed Web of Science ®Google Scholar
• Dejaco C, Harrer M, Waldhoer T, Miehsler W, Vogelsang H, Reinisch W. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. Aliment Pharmacol Ther. 2003;18(11–12):1113–1120
   PubMed Web of Science ®Google Scholar
• Aberra FN, Brensinger CM, Bilker WB, Lichtenstein GR, Lewis JD. Antibiotic use and the risk of flare of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2005;3(5):459–465
   PubMedGoogle Scholar
• Colombel JF, Lemann M, Cassagnou M, . A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol. 1999;94(3):674–678
   PubMed Web of Science ®Google Scholar
• Turunen UM, Farkkila MA, Hakala K, . Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology. 1998;115(5):1072–1078
   PubMed Web of Science ®Google Scholar
• Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105(3):501–523
   PubMed Web of Science ®Google Scholar
• McLaughlin SD, Walker AW, Churcher C, . The bacteriology of pouchitis: a molecular phylogenetic analysis using 16S rRNA gene cloning and sequencing. Ann Surg. 2010;252(1):90–98
   PubMed Web of Science ®Google Scholar
• Tyler AD, Knox N, Kabakchiev B, . Characterization of the gut-associated microbiome in inflammatory pouch complications following ileal pouch-anal anastomosis. PLoS One. 2013;8(9):e66934
   PubMed Web of Science ®Google Scholar
• Holubar SD, Cima RR, Sandborn WJ, Pardi DS. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev. 2010;(6):CD001176
   Google Scholar
• Yu ED, Shao Z, Shen B. Pouchitis. World J Gastroenterol. 2007;13(42):5598–5604
   PubMedGoogle Scholar
• Isaacs KL, Sandler RS, Abreu M, . Rifaximin for the treatment of active pouchitis: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis. 2007;13(10):1250–1255
   PubMed Web of Science ®Google Scholar
• Shen B, Remzi FH, Lopez AR, Queener E. Rifaximin for maintenance therapy in antibiotic-dependent pouchitis. BMC Gastroenterol. 2008;8:26
   PubMed Web of Science ®Google Scholar
• Gionchetti P, Rizzello F, Ferrieri A, . Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial. Dig Dis Sci. 1999;44(6):1220–1221
   PubMed Web of Science ®Google Scholar
• Sanders ME, Guarner F, Guerrant R, . An update on the use and investigation of probiotics in health and disease. Gut. 2013;62(5):787–796
   PubMed Web of Science ®Google Scholar